[The efficacy of cortexin and memantinol (memantine) in the treatment of cognitive impairment in patients with chronic cerebral ischemia].

Fedin AI

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2018Cited by 7 (Europe PMC)

PMID29460902DOI10.17116/jnevro20181181130-36PepBankPUB-29460902

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

1 result from studies that gave the peptide. 1 result from people.

01HumanObservational studyEfficacy outcome
In patients with chronic cerebral ischemia, Cortexin treatment was linked to improved scores across the cognitive scales.
In plain wordsIn patients with chronic cerebral ischemia, Cortexin treatment was linked to improved cognitive scores.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
IncreaseCognitive scale scores with Cortexin alone
Study
n = 388
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
A significant positive effect of treatment based on the scores on 4 cognitive scales was shown in both groups of patients.
2 context sentences(design, population, supporting numbers)
Summary · context
The authors present the results of the multicenter observational program 'KORMEN' that studied the efficacy of cortexin and memantinol in the treatment of cognitive impairment in patients with CCI.
Summary · context
Patients were stratified into two groups: cortexin group (n=388 (78.4%)) and cortexin + memantinol group.
Report a problemFND-2946090201

Studies that did not test the peptide alone3

In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cortexin (cortical polypeptide complex).

02HumanNot a test of Cortexin (cortical polypeptide complex) aloneObservational studyEfficacy outcome
In patients with chronic cerebral ischemia, Cortexin plus memantinol treatment was linked to improved cognitive scale scores.
In plain wordsIn patients with chronic cerebral ischemia, Cortexin plus memantinol was linked to improved cognitive scores.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
IncreaseCognitive scale scores with combination therapy
Study
n: not reported in source
Outcome group
Cognition and memory · Nervous system and cognition
Source sentences
Summary
A significant positive effect of treatment based on the scores on 4 cognitive scales was shown in both groups of patients.
2 context sentences(design, population, supporting numbers)
Summary · context
The authors present the results of the multicenter observational program 'KORMEN' that studied the efficacy of cortexin and memantinol in the treatment of cognitive impairment in patients with CCI.
Summary · context
Patients were stratified into two groups: cortexin group (n=388 (78.4%)) and cortexin + memantinol group.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).
Report a problemFND-2946090202
03HumanNot a test of Cortexin (cortical polypeptide complex) aloneObservational studyEfficacy outcome
In patients with severe cognitive impairment, adding memantinol to Cortexin was linked to better cognitive function than Cortexin alone.
In plain wordsIn patients with severe cognitive impairment, Cortexin plus memantinol was linked to better cognition than Cortexin alone.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
IncreaseCognitive function in severe impairment
Study
n: not reported in source
Comparator
Cortexin alone
Outcome group
Cognition and memory · Nervous system and cognition
Source sentences
Summary
The addition of memantinol significantly improved cognitive functions in patients with severe cognitive impairment (р<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
The authors present the results of the multicenter observational program 'KORMEN' that studied the efficacy of cortexin and memantinol in the treatment of cognitive impairment in patients with CCI.
Summary · context
Patients were stratified into two groups: cortexin group (n=388 (78.4%)) and cortexin + memantinol group.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).
Report a problemFND-2946090203
04HumanNot a test of Cortexin (cortical polypeptide complex) aloneObservational studySafety outcome
In patients with chronic cerebral ischemia, the study reported a confirmed safety profile for Cortexin and memantinol without event details.
In plain wordsIn patients with chronic cerebral ischemia, the study reported safety for the drugs without specific event data.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
Direction not reportedOverall safety profile
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
The safety profile of the drugs was confirmed.
2 context sentences(design, population, supporting numbers)
Summary · context
The authors present the results of the multicenter observational program 'KORMEN' that studied the efficacy of cortexin and memantinol in the treatment of cognitive impairment in patients with CCI.
Summary · context
Patients were stratified into two groups: cortexin group (n=388 (78.4%)) and cortexin + memantinol group.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).
Report a problemFND-2946090204

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.